WallStreetZenWallStreetZen

NYSE: HLN
Haleon PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their HLN stock forecasts and price targets.

Forecast return on equity

Is HLN forecast to generate an efficient return?

Company
10.76%
Industry
271.24%
Market
142.96%
HLN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HLN forecast to generate an efficient return on assets?

Company
5.07%
Industry
147.86%
HLN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HLN earnings per share forecast

What is HLN's earnings per share in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
$0.19-52.3%
Avg 2 year Forecast
$0.21-47.87%
Avg 3 year Forecast
$0.23-42.51%
HLN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

HLN revenue forecast

What is HLN's revenue in the next 3 years based on estimates from 21 analysts?

Avg 1 year Forecast
$11.4B-19.1%
Avg 2 year Forecast
$11.8B-15.77%
Avg 3 year Forecast
$12.4B-11.92%
HLN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HLN earnings growth forecast

How is HLN forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-17.96%
Industry
324.89%
Market
41%
HLN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
HLN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
HLN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

HLN revenue growth forecast

How is HLN forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-5.39%
Industry
121.12%
Market
24.86%
HLN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HLN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HLN vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
HLN$9.27N/AN/A
TAK$13.44N/AN/A
TEVA$20.48$24.60+20.12%Strong Buy
ZTS$144.09$175.60+21.87%Buy
NBIX$143.21$169.00+18.01%Strong Buy
View Top Pharmaceutical Stocks

Haleon Stock Forecast FAQ

What is HLN's earnings growth forecast for 2025-2027?

(NYSE: HLN) Haleon's forecast annual earnings growth rate of -17.96% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 324.89%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.

Haleon's earnings in 2025 is $1,872,727,272.On average, 22 Wall Street analysts forecast HLN's earnings for 2025 to be $1,711,373,963, with the lowest HLN earnings forecast at $1,585,110,173, and the highest HLN earnings forecast at $1,812,203,321. On average, 21 Wall Street analysts forecast HLN's earnings for 2026 to be $1,870,339,167, with the lowest HLN earnings forecast at $1,740,441,886, and the highest HLN earnings forecast at $1,960,268,053.

In 2027, HLN is forecast to generate $2,062,914,156 in earnings, with the lowest earnings forecast at $1,867,614,049 and the highest earnings forecast at $2,254,580,773.

If you're new to stock investing, here's how to buy Haleon stock.

What is HLN's revenue growth forecast for 2025-2027?

(NYSE: HLN) Haleon's forecast annual revenue growth rate of -5.39% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 121.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.

Haleon's revenue in 2025 is $14,588,311,688.On average, 21 Wall Street analysts forecast HLN's revenue for 2025 to be $103,182,042,713,921, with the lowest HLN revenue forecast at $97,005,109,089,001, and the highest HLN revenue forecast at $106,243,258,348,624. On average, 21 Wall Street analysts forecast HLN's revenue for 2026 to be $107,433,226,444,013, with the lowest HLN revenue forecast at $100,357,003,953,112, and the highest HLN revenue forecast at $111,693,493,900,024.

In 2027, HLN is forecast to generate $112,338,438,440,273 in revenue, with the lowest revenue forecast at $104,435,596,890,743 and the highest revenue forecast at $118,043,018,317,405.

What is HLN's forecast return on assets (ROA) for 2025-2028?

(NYSE: HLN) forecast ROA is 5.07%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 147.86%.

What is HLN's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: HLN) Haleon's current Earnings Per Share (EPS) is $0.41. On average, analysts forecast that HLN's EPS will be $0.19 for 2025, with the lowest EPS forecast at $0.17, and the highest EPS forecast at $0.20. On average, analysts forecast that HLN's EPS will be $0.21 for 2026, with the lowest EPS forecast at $0.19, and the highest EPS forecast at $0.22. In 2027, HLN's EPS is forecast to hit $0.23 (min: $0.21, max: $0.25).

What is HLN's forecast return on equity (ROE) for 2025-2028?

(NYSE: HLN) forecast ROE is 10.76%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.